Hospital Groups Cite Supreme Court Decision in Latest Briefs Backing Feds in Lilly and AstraZeneca 340B Cases

Hospital groups urged two federal appeals court to back the government in its fight to force Lilly and AstraZeneca to end restrictions on 340B pricing when covered entities use contract pharmacies.

Five groups that represent 340B hospitals have filed briefs in two federal appeals courts backing the federal government in its fight to force drug manufacturers Eli Lilly and AstraZeneca to end restrictions on 340B drug discounts when covered

Read More »

Novo Nordisk, Sanofi, and Feds Trade Arguments in 340B Contract Pharmacy Litigation

Novo Nordisk and Sanofi urged a federal appeals court in Philadelphia to reverse a district judge’s ruling that their denials on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.

Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.

Read More »

Breaking News

In Important Ruling, Federal Appeals Court Says Health Center May Challenge 340B Patient Definition’s Legality

A federal appeals court says South Carolina health center Genesis Healthcare has the right to challenge the 340B patient definition's legality in a lower federal court.

A federal appeals court ruled unanimously this morning that a South Carolina health center has the right to challenge the legality of the government’s 340B patient definition in a lower federal court.

Please Login or Become

Read More »

AHA Tells HHS It Wants Prompt Repayment for All Years Hospitals’ Medicare Drug Payments Have Been Cut

The AHA wants 340B hospitals to be promptly repaid for all "illegally cut" Medicare Part B drug reimbursement.

The American Hospital Association wants to discuss with U.S. Health and Human Services Secretary Xavier Becerra how 340B hospitals should be promptly repaid “for all of the years (2018-2022) in which the Centers for Medicare & Medicaid Services

Read More »

Feds Ask Appeals Court to Partially Reverse Ruling on Lilly’s 340B Contract Pharmacy Policy

The federal government asked an appeals court to affirm one part and vacate another of a lower court's opinion about the legality of Lilly's 340B contract pharmacy restrictions.

A federal district judge was right to decide that drug manufacturer Lilly cannot tie strings to 340B pricing on its drugs, the U.S. Justice Department told a federal appeals court in Chicago on Friday.

Please Login

Read More »

Clinics Pay Gilead $33 Million to Settle Fraud Claims Involving 340B-Related PrEP Transactions

A group of Florida healthcare providers will pay $33 million to settle Gilead's claims the group made fraudulent 340B-related transactions involving the company’s HIV pre-exposure prophylaxis drugs.

One of two groups of Florida health care providers that drug maker Gilead accused of making fraudulent 340B-related transactions involving the company’s HIV pre-exposure prophylaxis drugs agreed last week to settle Gilead’s claims against it for $33 million.

Read More »

Supreme Court DSH Calculation Ruling Leaves 340B Status Quo in Place, Experts Say

A U.S. Supreme Court decision about the Medicare DSH adjustment percentage calculation is expected to have little effect on hospitals currently in the 340B drug pricing program.

A U.S. Supreme Court decision last week about the Medicare disproportionate share adjustment percentage calculation will have little effect on hospitals currently in the 340B drug pricing program, experts say.

Please Login or Become a Paid

Read More »

340B Report Publisher and CEO: Takeaways from Supreme Court’s Part B Cuts Decision

The U.S. Supreme Court opinion striking down huge cuts in 340B hospitals’ Medicare Part B drug reimbursement “is a clear and much welcome victory" for the hospitals, 340B Report Publisher and CEO Ted Slafsky says.

The U.S. Supreme Court’s unanimous June 15 ruling that huge cuts in 340B hospitals’ Medicare Part B drug reimbursement were unlawful “is a clear and much welcome victory for 340B hospitals,” 340B Report Publisher and CEO Ted Slafsky

Read More »

The Supreme Court Aftermath: What Comes Next in Fight Over Medicare Part B Drug Payments to 340B Hospitals?

Yesterday's U.S. Supreme Court's opinion about deep cuts in 340B hospitals’ Medicare Part B drug reimbursement ended Phase 1 of the debate. Phase 2 gets underway next month in lower federal courts in Washington, D.C., and in the pages of the Federal register.

Phase 2 of the debate over huge cuts in 340B hospitals’ Medicare Part B drug reimbursement is gearing up. It will be played out in a federal appeals court in Washington, D.C., a federal district court in Washington, and the pages

Read More »

Breaking News

U.S. Supreme Court Strikes Down Medicare Part B Drug Payment Cuts for 340B Hospitals in 2018 and 2019

The U.S. Supreme Court today struck down deep Medicare Part B drug reimbursement cuts for many 340B hospitals during 2018 and 2019. The decision does not affect continuation of the cuts in 2020 through this year, however.

The U.S. Supreme Court ruled unanimously this morning that the federal government unlawfully slashed Medicare Part B drug reimbursement for many 340B hospitals by almost 30 percent during 2018 and 2019.

Please Login or

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report